| Literature DB >> 35121950 |
Scott V Bratman1,2,3, S Y Cindy Yang1,3, Marco A J Iafolla3,4, Zhihui Liu3,5, Aaron R Hansen3,4, Philippe L Bedard3,4, Stephanie Lheureux3,4, Anna Spreafico3,4, Albiruni Abdul Razak3,4, Svetlana Shchegrova6, Maggie Louie6, Paul Billings6, Bernhard Zimmermann6, Himanshu Sethi6, Alexey Aleshin6, Dax Torti7, Kayla Marsh7, Jenna Eagles7, Iulia Cirlan3, Youstina Hanna3, Derek L Clouthier3, Scott C Lien3,8, Pamela S Ohashi3,8, Wei Xu3,5, Lillian L Siu9,10, Trevor J Pugh11,12,13.
Abstract
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with cancer. However, existing biomarkers do not reliably predict treatment response across diverse cancer types. Limited data exist to show how serial circulating tumor DNA (ctDNA) testing may perform as a predictive biomarker in patients receiving ICB. We conducted a prospective phase II clinical trial to assess ctDNA in five distinct cohorts of patients with advanced solid tumors treated with pembrolizumab (NCT02644369). We applied bespoke ctDNA assays to 316 serial plasma samples obtained at baseline and every three cycles from 94 patients. Baseline ctDNA concentration correlated with progression-free survival, overall survival, clinical response and clinical benefit. This association became stronger when considering ctDNA kinetics during treatment. All 12 patients with ctDNA clearance during treatment were alive with median 25 months follow up. This study demonstrates the potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB.Entities:
Mesh：
Substances：
Year: 2020 PMID： 35121950 DOI： 10.1038/s43018-020-0096-5
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347